DexCom (DXCM) Projected to Post Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to be announcing its earnings results after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of $0.50 per share and revenue of $1.10 billion for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

DexCom Stock Down 2.1 %

Shares of DXCM stock opened at $86.38 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a 50 day moving average of $81.94 and a 200-day moving average of $74.97. The firm has a market cap of $33.74 billion, a PE ratio of 51.72, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Wells Fargo & Company raised their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.